事实证明,新的单一流感艾滋病毒治疗与目前的多种流感治疗办法一样有效,没有新的安全问题。 A new single-pill HIV treatment proved as effective as current multi-pill regimens, with no new safety issues.

吉利德科学公司的 3 期 ARTISTRY-1 试验发现，在病毒学抑制的成人中，结合比克替拉韦和来那卡韦的单片 HIV 方案不劣于目前的多药治疗，在第 48 周时将 HIV-1 RNA 维持在 50 拷贝/mL 以下。 Gilead Sciences' Phase 3 ARTISTRY-1 trial found a single-tablet HIV regimen combining bictegravir and lenacapavir was non-inferior to current multi-pill treatments in virologically suppressed adults, maintaining HIV-1 RNA below 50 copies/mL at week 48. 疗程良好,没有新的安全关切。 The regimen was well-tolerated with no new safety concerns. 正在进行中的ARTISTRY-2试验,对Biktarvy的病人采用同样的治疗方法,预计到年底将得出最显著的结果。 Top-line results from the ongoing ARTISTRY-2 trial, evaluating the same regimen in patients on Biktarvy, are expected by year-end. Gilead计划向监管机构提交数据。 Gilead plans to submit data to regulators.